425: ATAI Amends Beckley Psytech Acquisition Terms

ATAI Life Sciences N.V. has amended its Share Purchase Agreement for Beckley Psytech, adjusting share allocations and permitted transaction costs.

Summary

• ATAI Life Sciences N.V. entered into a Side Letter Deed to amend the Share Purchase Agreement (SPA) with Beckley Psytech Limited, originally dated June 2, 2025.
• The number of ATAI ordinary shares to be issued to Beckley Psytech shareholders will be reduced on a pro-rata basis by an aggregate of 1,221,712 shares.
• A total of 103,823,190 ATAI shares will now be distributed to Beckley Psytech shareholders or underlie Replacement Awards for certain optionholders.
• 900,901 ATAI shares will be issued to Cantor Fitzgerald & Co (CF&CO) for financial advisory services rendered to Beckley Psytech; these shares will not be subject to lock-up restrictions.
• The definition of 'Permitted Costs' has been revised to adjust the amount of permitted leakage and to include certain payments to CF&CO.
• Permitted Leakage related to Transaction Costs or Carve-out Costs, up to $6,780,500 in aggregate, will now be settled by a pro-rata reduction in Consideration Shares rather than cash.
• The maximum aggregate amount for certain acquisition or carve-out related costs or expenses considered 'Permitted Costs' has been increased from $2,000,000 to $3,780,500.
• ATAI may, at its sole discretion, allow up to 0.75% of the Consideration Shares to be released from lock-up provisions to enable certain Beckley Optionholders to cover tax obligations.

Sentiment

Score: 5

Explanation: The filing details amendments to an existing acquisition agreement. While there's a slight dilution from the issuance of shares to the financial advisor and an increase in permitted costs, these are largely procedural adjustments to facilitate the acquisition. The reduction in shares to Beckley shareholders partially offsets other dilutive aspects. Overall, it's a neutral update on an ongoing strategic transaction.

Positives

• The reduction in shares issued to Beckley Psytech shareholders (1,221,712 shares) could be seen as a positive for existing ATAI shareholders, as it reduces dilution from that specific group.
• The settlement of up to $6,780,500 in leakage costs via a reduction in Consideration Shares, rather than cash, preserves ATAI's cash reserves.

Negatives

• The issuance of 900,901 ATAI shares to Cantor Fitzgerald & Co. for advisory services represents additional dilution for existing ATAI shareholders.
• The shares issued to Cantor Fitzgerald & Co. are not subject to any lock-up restrictions, potentially allowing for immediate sale and downward pressure on ATAI's stock price.
• The increase in the aggregate amount of 'Permitted Costs' for Transaction Costs or Carve-out Costs from $2,000,000 to $3,780,500 indicates higher-than-initially-expected transaction-related expenses.

Risks

• The Proposed Transactions (acquisition of Beckley Psytech and redomiciliation) may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• Failure to realize the anticipated benefits of the Proposed Transactions.
• The possibility that any or all conditions to the consummation of the Proposed Transactions may not be satisfied or waived.
• The occurrence of any event, change, or other circumstance that could lead to the termination of the Share Purchase Agreement.
• The effects of the redomiciliation transaction on the trading, liquidity, and price of ATAI securities.
• The effect of the announcement or pendency of the Proposed Transactions on ATAI's ability to retain and hire key personnel, or its operating results and business generally.

Future Outlook

The company expects the acquisition of Beckley Psytech Limited and a redomiciliation transaction to proceed, subject to shareholder approvals and satisfaction of various conditions. The filing reiterates the potential for these transactions to not be completed in a timely manner or at all, and highlights risks related to realizing anticipated benefits, retaining key personnel, and the impact on ATAI's securities.

Industry Context

This amendment reflects ongoing adjustments common in complex M&A transactions within the biotechnology and pharmaceutical sectors, particularly in emerging fields like psychedelic medicine. The acquisition of Beckley Psytech aligns with ATAI's strategy to expand its pipeline in mental health treatments. The involvement of financial advisors like Cantor Fitzgerald & Co. and the detailed adjustments to share consideration and cost definitions are standard practices in ensuring deal closure and managing financial implications.

Stakeholder Impact

• Shareholders (ATAI): Will experience dilution from the issuance of 900,901 shares to Cantor Fitzgerald & Co. and the 103,823,190 shares for the acquisition, though the initial consideration was reduced by 1,221,712 shares. The shares issued to CF&CO are not locked up, potentially increasing selling pressure.
• Beckley Psytech Shareholders/Optionholders: Will receive a slightly reduced number of ATAI shares as consideration (1,221,712 fewer shares in aggregate) and may have up to 0.75% of their shares released from lock-up for tax purposes.
• Cantor Fitzgerald & Co.: Will receive 900,901 ATAI shares as payment for financial advisory services, with no lock-up restrictions.

Next Steps

• Shareholders of ATAI must notify the company of their identity and intention to attend the Extraordinary General Meeting by October 31, 2025, to be eligible to attend and vote.
• The closing of the acquisition of Beckley Psytech Limited is pending, subject to various conditions and shareholder approvals.
• ATAI Life Sciences Luxembourg S.A. has filed a registration statement on Form S-4, which includes a proxy statement, in connection with the Proposed Transactions.
• A prospectus supplement will be filed by ATAI immediately following the closing of the transaction to register for resale the shares received by Cantor Fitzgerald & Co.
• Replacement Awards, if elected by ATAI, will be granted to Beckley Optionholders within five business days of Closing.
• The Seller Representative will deliver schedules detailing share calculations and option treatments prior to the Shareholders Meeting and Closing.

Key Dates

Recommendation

This filing provides an update on the ongoing acquisition of Beckley Psytech, detailing amendments to the share purchase agreement. While there are adjustments to share allocations and permitted costs, these are largely procedural and expected in a complex M&A transaction. The issuance of shares to a financial advisor and the increase in permitted costs introduce some dilution and higher expenses, but these are partially offset by a reduction in shares to Beckley shareholders and the settlement of leakage costs via shares rather than cash. The core strategic rationale for the acquisition remains unchanged, and the risks outlined are typical for such transactions. Investors should hold to see the completion of the acquisition and subsequent integration, as the long-term impact will depend on the success of the combined entity's pipeline and market execution.

Keywords

ATAI Life Sciences, Beckley Psytech, Acquisition, Share Purchase Agreement, Merger, Psychedelic Medicine, Biotechnology, SEC Filing, Form 425, Share Dilution, Transaction Costs, Corporate Governance